Telix Pharmaceuticals Limited Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Telix Pharmaceuticals Limited (TLPPF) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $19.15 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-02-20
AUD
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2024-12-31 | 19.66M AUD 20-F · filed 2025-02-24 |
| 2023-12-31 | 8.79M AUD 20-F · filed 2025-02-24 |
| 2022-12-31 | 8.11M AUD 20-F · filed 2025-02-24 |
USD
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2025-12-31 | $19.15M 20-F · filed 2026-02-20 |
| 2024-12-31 | $12.93M 20-F · filed 2026-02-20 |
| 2023-12-31 | $5.85M 20-F · filed 2026-02-20 |